ClinicalTrials.gg
CompletedNCT06116968Updated Jan 21, 2026

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

A Phase 3 interventional study of Aficamten in Obstructive Hypertrophic Cardiomyopathy, sponsored by Corxel Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Corxel Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.

Enrollment
8th of 11
40 · median 96
Started
2023
with 2 others
Phase 3
5 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
2 of 11
Corxel Pharmaceuticals

Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 8th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, and was the 8th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aficamten

aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of a Cytokinetics trial investigating CK-3773274
  2. ≥55% at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  1. Has participated in another device or drug study or received an investigational device or drug \<1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
  2. Since completion of a previous study of aficamten has:Developed new-onset paroxysmal or permanent atrial fibrillation (AF) requiring rhythm restoring treatment (e.g., direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) \<30 days prior to screening. Patient may rescreen for JX01003 after 30 days if heart rate (HR) \<100 bpm and/or rhythm is stable >30 days.
  3. Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation).
  4. Had a confirmed \<40% with an associated dose interruption during participation in a prior study with aficamten.
  5. History of appropriate implantable cardioverter defibrillator (ICD) shock within 30 days prior to screening.
  6. Has received treatment with mavacamten.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Aficamten

    Patients in this arm take daily dose of Aficamten. Each patient will start at the lowest dose (5 mg) in the pre-specified dose range and undergo dose titration up to a maximum of 20 mg.

    Drug: Aficamten

Interventions

06

What researchers measure

Primary outcomes

  1. Patient incidence of reported adverse events (AEs)

    Time frame: Baseline to End of study, up to 2 years

  2. Patient incidence of reported serious adverse events (SAEs )

    Time frame: Baseline to End of study, up to 2 years

  3. Patient incidence of LVEF<50% & LVEF <40%

    Time frame: Baseline to End of study, up to 2 years

Secondary outcomes

  1. Peak LVOT-G at rest and with Valsalva provocation

    Time frame: Change from baseline values to week 48 at 12-week intervals;

  2. Proportion of patients with resting LVOT-G <50 mmHg

    Time frame: Change from baseline values to week 48 at 12-week intervals;

  3. Proportion of patients with resting LVOT-G <30 mmHg

    Time frame: Change from baseline values to week 48 at 12-week intervals;

  4. Proportion of patients with post-Valsalva LVOT-G <50 mmHg

    Time frame: Change from baseline values to week 48 at 12-week intervals;

  5. Proportion of patients with post-Valsalva LVOT-G <30 mmHg

    Time frame: Change from baseline values to week 48 at 12-week intervals;

  6. Proportion of patients with LVEF ≥50%, resting LVOT-G <30 mmHg, and post-Valsalva LVOT-G <50 mmHg

    Time frame: Change from baseline values to week 48 at 12-week intervals;

  7. First resting LVOT-G <50 mmHg

    Time frame: Time to the following event through last follow-up, up to 2 years.

  8. First resting LVOT-G <30 mmHg

    Time frame: Time to the following event through last follow-up, up to 2 years.

  9. First post-Valsalva LVOT-G <50 mmHg

    Time frame: Time to the following event through last follow-up, up to 2 years.

  10. First post-Valsalva LVOT-G <30 mmHg

    Time frame: Time to the following event through last follow-up, up to 2 years.

  11. First LVEF ≥50%, resting LVOT-G <30 mmHg, and post-Valsalva LVOT-G <50 mmHg

    Time frame: Time to the following event through last follow-up, up to 2 years.

07

Study locations

12 sites
  • Beijing Anzhen Hospital
    Beijing, China
  • Beijing Chao-yang Hospital, Capital Medical University
    Beijing, China
  • Fuwai Hospital, CAMS & PUMC
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • Nanfang Hospital
    Guangzhou, China
  • The Second Affiliated Hospital of Nanchang University
    Jiangxi, China
  • The First Hospital of Jilin University
    Jilin City, China
  • Shengjing Hospital of China Medical University
    Shenyang, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Oct 2025, 23 months.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Nov 3, 2023
StartActual
Nov 14, 2023
Primary completionActual
Oct 20, 2025
CompletionActual
Oct 20, 2025
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116968
Lead sponsor
Corxel Pharmaceuticals
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Nov 14, 2023
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Jan 21, 2026

Study contacts

Yuhui Zhang, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion